Study Objectives
To determine
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
the percentage of LN patients in histopathological remission after 12 months of standard of care immunosuppression.
To correlate
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
histological and immunological (immune deposits) response to therapy with clinical response.
To evaluate
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
whether therapeutic decisions steered by the results of a per-protocol repeat kidney biopsy improve renal outcomes compared with a matched control group of patients who did not undergo repeat kidney biopsy.
To generate data
![line](http://rebiolup.com/wp-content/uploads/2020/07/line.jpg)
on how to evaluate response to therapy in pure membranous LN (ISN/RPS class V), as well as the value of the information retrieved from repeat kidney biopsies in portending long-term renal prognosis in this LN subset.